INTRODUCTION

Lower extremity venous disorders encompass a spectrum of functional abnormalities of the venous system including chronic venous disease and chronic venous insufficiency (CVI). Clinical manifestations of CVI include leg pain, edema, skin changes such as hyperpigmentation (hemosiderosis), venous eczema, lipodermatosclerosis, and active or healed ulcers. In the United States, it is estimated that approximately 2.5 million people (between 10% and 35% of adults) have clinical manifestations of CVI.1,2 Venous leg ulcers (VLUs) affect 600,000 Americans or 4% of adults 65 years of age or older1; these ulcers account for up to 90% of all leg ulcers. The prevalence of CVI and VLU are expected to grow as the population ages.3

Clinical outcomes in patients with CVI and VLUs are poor. Persons with CVI frequently experience delayed healing and up to 97% experience recurrent ulcerations.4 Half of these recurrences will occur within 10 years of development of the first VLU,2 consuming substantial health care resources. Ma and colleagues5 evaluated the cost of treating VLUs in 84 patients residing in the United States. The mean direct cost of treatment over a 6-month period was $15,732. Sixty percent of participants (n = 50) achieved healing with a mean time of 122 days (range, 6-379 days); the average costs were $10,563 (range, $430-$50,967). Forty-four patients (52%) were treated with compression therapy and local ulcer care; their mean cost for VLU care was $12,304. Seventeen patients (20%) with VLUs did not heal in 6 months; their mean costs were $33,907 (range, $390-$321,730). Ma's group5 measured only direct costs; their estimates did not include loss of income, and items not covered by insurance or travel to medical offices. Rice and associates3 estimated the incremental per-patient and overall payer burden of VLUs in the United States; they extracted data from a Medicare and private insurer's databases and matched persons with VLU to persons without VLU. Persons with VLU who were ensured by Medicare incurred $6391 more costs ($418,986 vs $12,595) than age-matched subjects without VLU. Similarly, persons with private insurance coverage incurred $7030 higher costs ($13,653 vs $6623) than subjects without VLU. In addition, privately insured persons with VLU missed more days from work than did persons without VLU (14 vs 10 days; P < .0001), resulting in significantly higher work loss costs.3

Compression is the oldest and most widely used intervention for management of CVI. Correctly applied compression therapy is the cornerstone of treatment and has been shown to improve healing rates in patients with existing VLUs and reduce the likelihood of ulcer recurrence.2,6-10 High-quality systematic reviews indicate that primary prevention with compression stockings improve CVI-related symptoms such as aching and itching when compared to no compression.2,8 Compression has also been shown to improve healing of VLU when compared to no compression.2,7-9

Despite multiple guidelines focusing on prevention and management of CVI and venous ulcers, application of compression in daily practice remains a challenge. While the various clinical guidelines concur that compression is a cornerstone of VLU treatment and prevention, they lack adequate detail concerning which form of compression is best for each patient.2,7-9,11,12 This decision is especially complex, given the variety of influencing factors such as the goal of therapy (primary prevention of venous ulcers in patients with CVI, prevention of ulcer recurrence, or management of a current ulcer), patient tolerance, and variable resources needed to obtain and apply compression.

CONSTRUCTION OF THE ALGORITHM

In an effort to provide clinical guidance for providing individualized care to patients with CVI across the care continuum, the WOCN Society elected to develop an evidence- and consensus-based algorithm for compression in the patient with CVI. Society leaders assembled a Task Force of 3 expert clinicians in order to (1) identify evidence supporting the use of compression for prevention and management of VLU; (2) develop evidence-based statements needed to support the algorithm; (3) develop consensus-based statements needed to support decisions and pathways not supported by higher-level evidence; and (4) establish face validity of a first draft of the VLU algorithm. Subsequently, a group of 20 key opinion leaders was convened to review the draft algorithm and evidence-based supporting statements and reach consensus on statements lacking adequate supporting evidence. Finally, an independent group of clinicians with expertise in CVI and venous ulcer care was asked to review the algorithm, establish its content validity, and suggest changes. This article summarizes each of these steps in the development of this landmark algorithm.

Scoping Literature Review

Three certified WOC nurses (C.R., S.Y., and L.M.) with clinical expertise in chronic wounds of the lower extremity were appointed by WOCN Society leadership to act as a Task Force for generation and validation of the consensus and evidence-based algorithm for use of compression in the prevention and management of CVI and VLU. Task Force members began by identifying aims and search terms required for a scoping literature review. While the criteria that define a scoping literature search continue to evolve, it can be broadly defined as a synthesis of the literature that maps key concepts, types of evidence, and gaps in research by systematically searching, retrieving, and synthesizing current best evidence.13,14 To maximize efficiency during this process, the Task Force appointed a facilitator (M.G.) with experience in this type of literature review and algorithm construction.

The scoping literature review was completed using the basic steps recommended by Colquhoun and colleagues.13 This review was guided by the following aim: to identify evidence concerning the use of compression for prevention and management of CVI and VLU. The review was divided into 2 phases. In the first phase, we searched the literature from 2005 to 2015 in order to identify evidence-based clinical practice guidelines for prevention and management of VLU and CVI. The search terms for this search were "venous ulcers," "venous leg ulcers," "chronic venous insufficiency," "compression," and "clinical practice guideline" along with the MESH terms "varicose ulcers," "venous insufficiency," "compression bandages," "compression stockings," "intermittent pneumatic compression devices," and "practice guidelines." We searched the MEDLINE and CINAHL electronic databases, Cochrane Library of Systematic Reviews, and United States Agency for Health Research and Quality National Guideline Clearinghouse. We limited the search to guidelines published in English and supported by an explicitly defined methodology for systematic review and generation of recommendations for clinical practice. This search identified 8 clinical practice guidelines that met inclusion criteria; all were used in construction of the algorithm (Table 1).

TABLE 1. Clinical Practice Guidelines Used as Basis for Development of the Algorithm

A second literature search was then conducted of the MEDLINE and CINAHL electronic databases from 2010 through 2015. This review more closely used techniques identified for systematic literature reviews.17 The aim of this phase of the scoping literature review was to identify the most recent studies focusing on the use of compression for prevention and management of CVI and VLU that may not have been included in the various Clinical Practice Guidelines identified during the first phase of our search. Key terms used for this search were "venous ulcers," "venous leg ulcers," "chronic venous insufficiency," "compression," and "clinical practice guideline" along with the MESH terms "varicose ulcers," "venous insufficiency," "compression bandages," "compression stockings," and "intermittent pneumatic compression devices." We limited the review to randomized controlled trials, systematic reviews with meta-analysis, and nonrandomized comparison cohort studies that examined the efficacy of various forms of compression on prevention and management of VLU, primary prevention of VLU in persons with CVI, studies comparing the various forms of compression, and studies evaluating adherence to compression (an essential component of effectiveness). We excluded studies comparing compression products not available in the United States, studies performed in healthy volunteers, studies measuring outcomes other than VLU healing in persons with CVI, and studies measuring intermediate outcomes such as the magnitude of compression created when specific compression devices are applied to the lower extremities. The search was also limited to studies published in the English language. This review yielded 151 titles. Following elimination of foreign language articles, duplicate publications, and articles not reporting original data, the search was limited to 50 papers. Each of the 3 task force members completed title and abstract search of the remaining 50 titles for relevancy. Based on this review, 17 articles were retrieved and read in full by each task force member to determine if the study met inclusion criteria. Methodological quality was judged for each study by all 3 Task Force members; the risk of bias varied from low to high and most studies were found to have moderate to higher risk of bias. Nevertheless, no study was eliminated based on methodological weaknesses alone. Disagreements concerning study inclusion and methodological quality were resolved by discussion moderated by the Task Force facilitator. Eleven studies were selected that also provided a basis for evidence-based decision points and pathways within the algorithm (Table 2).

TABLE 2. Individual Studies Included in Generation of Statement for Algorithm Development

The Task Force also identified and retrieved 9 key references used as a background for the algorithm.8,29-36 These references were used to provide supplemental materials for the algorithm.

Generation of Consensus- and Evidence-Based Statements and Development of the First Draft

Results from this scoping review were used to generate clinical decision points and various pathways for the algorithm. The strength of evidence from these statements was ranked using a 3-point ordinal scale adapted from the Level of Evidence Rating found in the WOCN Clinical Practice Guideline for Management of Wounds in Patients with Lower-Extremity Venous Disease37 and the Strength of Recommendations Taxonomy (SORT) from the American Academy of Family Physicians (Table 3). Twenty-seven evidence-based statements were generated from the findings of the scoping literature review (Table 4).

TABLE 3. Levels of Evidence Taxonomy for Supporting Statements

TABLE 4. Evidence-Based Statements Used in Construction of Algorithm

Following the scoping literature review and evidence-based statement development, the Task Force constructed a first draft algorithm via a series of Web-based conference calls and face-to-face meetings. Members of the Task Force evaluated the face validity of this first draft at multiple points during its development by identifying representative patient scenarios at their facilities and creating hypothetical scenarios and following each patient through the algorithm to ensure that the processes followed (e.g., assessments, considerations, reassessments), decision points, interim, and end results (e.g., recommendations for use of compression therapy) were comprehensive, feasible, and appropriate. Based on extensive discussion, the Task Force decided that the algorithm would focus on selection and application of compression therapy for the primary prevention, treatment, and prevention of recurrence of VLU associated with CVI.

As we generated this first draft of the algorithm, Task Force members soon realized that multiple decision points and supplemental recommendations lacked adequate supporting evidence. As a result, the Task Force generated 38 statements from the draft algorithm that lacked sufficient evidence to be deemed evidence-based (ie, Level of Evidence C). Rather than rely on agreement from the 3-member core group, the Task Force sought formal input from a representative group clinical experts who provide care for these patients. A Consensus Panel was brought together that represented the variety of clinicians (nurses, physicians, physical therapists) who care for persons with VLU and CVI, and the varied settings that compression and associated management of VLU and CVI occur (acute, ambulatory, long-term, and home health care settings) (Table 5). Geographic diversity also influenced the choice of panel members. Invitations were extended to executive leaders of relevant professional organizations, authors of relevant clinical practice guidelines, and basic and applied scientists conducting research in this area of practice. Twenty persons were empaneled; 12 (60%) were advanced practice nurses, 2 (10%) were specialty practice RNs, 2 (10%) were physical therapists, 2 (10%) were researchers, 1 was a researcher with training as an engineer, and 1 was a surgeon. Eighty percent (n = 16) had national certification in wound care.

TABLE 5. Consensus Panel Experts (N = 20a)

The 2-day conference began with a summary of preconference activities and a brief state-of-the-science presentation on current practice in the area of compression for CVI and VLUs. This presentation was followed by introduction of the initial draft of the algorithm and discussion of the evidence-based statements previously generated; several statements were clarified based on panel member input.

Nevertheless, the main task of the Consensus Panel was to reach formal consensus on statements guiding decision points and pathways of the algorithm that were not supported by level A or B evidence. The consensus process was facilitated by a clinician (M.G.) who does not routinely care for persons with CVI and VLU but has general knowledge of chronic wound care and prior experience in this type of facilitation. Consensus on each statement was obtained based on the principles outlined by Murphy and colleagues,39 using 80% agreement as the criterion for obtaining consensus. Statements were initially read to panelists and an initial vote was taken; clinicians were asked whether they agreed or disagreed with the recommendation for care or management expressed by the statement. If consensus was not achieved on the first vote, facilitated discussion occurred and the statement was edited based on panel member input. This process was repeated for up to 3 rounds of discussion until consensus was reached by formal vote. If consensus could not be reached after 3 rounds of discussion, or the statement deemed irrelevant to algorithm development, the statement was classified as "unable to reach consensus" and removed from further discussion. An interactive software program and wireless response system (Audio Visual One, Ltd, Bedford Park, Illinois) was used for all consensus votes. An electronic system was selected because it allowed feedback concerning progress toward consensus within a matter of seconds, and because it enabled anonymous voting by participants, thus reducing the risk of bias associated with public voting. As a result of this conference, consensus was reached on all statements used to support decision points and supplemental materials within the algorithm; no statements were eliminated (Table 6).

TABLE 6. Consensus Statements Used for Algorithm Construction

Following the conference, the Task Force revised the algorithm to incorporate the revised consensus-based and evidence-based statements into a second draft of the algorithm. This draft also incorporated supplemental materials deemed necessary since the algorithm is intended for use by a variety of clinicians with variable knowledge of CVI and VLU prevention and management.

Content Validation and Generation of the Final Draft

The process used for content validation was based on the technique described by Waltz and Bausell40 and subsequently modified by Lynn41 and Grant and Davis.42 A data collection form was developed to evaluate content validity of the algorithm and 21 experts in the field of CVI and VLU prevention and management, including use of compression, were identified (Table 7). The form contained demographic data regarding professional and educational background of respondents, and the number of years of experience in wound care and/or research. Nine sections representing various pathways in the algorithm were developed. Content experts were asked to rank individual items on a scale of 1 to 4, where 1 indicated not relevant/appropriate; 2 indicated unable to assess relevance without revision, 3 indicated relevant but needs minor alteration, and 4 indicated very relevant and appropriate. This second group of clinical experts was also given the opportunity to provide qualitative feedback (written comments and suggestions) on the comprehensiveness of the algorithm, omissions of essential content, and suggest changes to improve clarity, parsimony, and relevance.

TABLE 7. Content Validation Experts (N = 21)

Data were analyzed using Statistical Analysis Software version 9.4 (SAS Institute Inc., Cary, North Carolina). Data were coded and entered by a single data coordinator, analyzed by the biostatistician, and reviewed by the authors of this article. Content validity ratings were entered for 9 individual sections of the algorithm and the overall algorithm, and the content validity index was calculated for each section and the overall algorithm.43

The content validity index for the overall algorithm was 0.86, which is well above the suggested cut-point of 0.78 suggested by Polit and Beck44 for establishing content validity based on feedback from 3 or more reviewers. The content validity indices for the 9 pathways of the algorithm varied from 0.86 to 1.0 (Table 8). These findings indicate that the majority of expert panelists found that the overall algorithm and each of its 9 pathways were "very relevant and appropriate" or "relevant and needed only minor alteration."

TABLE 8. Content Validation Indices for the Algorithm

Content validators were also asked to provide qualitative feedback for the overall algorithm and each of its 9 pathways. Qualitative feedback focused on language used in the algorithm, options for therapies to complement the effectiveness of compression such as pharmacological agents, parameters for Ankle Brachial Index (ABI), also known as Ankle Brachial Pressure Index (ABPI) testing indicating clinically relevant arterial disease, a desire for more specific follow-up times, and suggestions for various additions to assessment of patients with CVI. The Task Force made multiple changes to the algorithm based on this qualitative feedback.

ALGORITHM FOR COMPRESSION CVI WITH AND WITHOUT VLU

The target audience for the algorithm includes nurses, specialty and advanced practice providers (wound care nurses, WOC nurses, vascular nurses, nurse practitioners, clinical nurse specialists, physician's assistants, etc), physicians (hospitalists, primary care physicians, vascular and other surgeons), physical therapists, and occupational therapists. The algorithm was designed for adult patients in acute care facilities (critical care, medical-surgical, orthopedic, rehabilitation units, and the emergency department), long-term acute care facilities, outpatient clinics, long-term care/skilled nursing homes, and home care settings.

Both the Task Force and Consensus Panel members engaged in extensive discussion concerning the importance of a classification system for CVI to enable standardization of assessment, management, and treatment of VLU, including compression. Chronic venous insufficiency can be described in terms of the well-established Clinical, Etiology, Anatomic, Pathophysiology (CEAP) classification system developed by an ad hoc committee of the American Venous Forum in 1994 and revised by an international consensus committee in 2004.45,46 This classification system has 7 categories (0-6) defined by the presence or absence of signs or symptoms. Strategies for the prevention of the progression of CVI from "pre-ulcer stages" CEAP C1 to C5 should be implemented to avoid focusing on the treatment of the ulcer only.

Users enter the algorithm when a patient presents with complaints related to their lower extremities (see the Figure). The clinician begins with review of the medical record, followed by completion of a health history and focused physical exam. Once assessment is complete, the clinician should determine the need for appropriate diagnostic studies, which may include ABI/ABPI testing.37,47 If access to results is delayed, the clinician may continue the differential diagnosis and refer to tools identified in the algorithm. If patient is found to have a disease or wound of other etiology (eg, lymphedema, lipedema, arterial, or neuropathic), the user should follow facility protocol or practice guideline for those conditions.37 Periodic patient reassessment of the lower extremities should occur on a regular basis.

Figure. Algorithm for compression CVI with and without VLU.

If the patient's lower extremity complaints and diagnostic tests are determined to be unrelated to venous disease (CEAP 0), the clinician is guided to provide education promoting leg health. These patients should be reassessed at least annually to identify any new or worsening problems with the legs; reassessment may be integrated with a general physical examination.

Figure. Algorithm for compression CVI with and without VLU.

Figure. Algorithm for compression CVI with and without VLU.

Figure. Algorithm for compression CVI with and without VLU.

When assessment reveals CVI, the clinician is directed to determine the clinical CEAP level.45,46 Patients with no current or past wound are classified as clinical CEAP 1-4. Those with healed wounds are clinical CEAP 5 and those with an active wound are classified as clinical CEAP 6.

For patients classified as clinical CEAP 1-2, treatment is based on presence and severity of symptoms. The clinician must first determine the need for compression. If compression is not needed, the clinician is guided to provide education promoting leg health from an expanded list. When compression is needed, the clinician must take into consideration individual patient characteristics, such as dexterity, mobility, preference, pain level cost, caregiver resources, and size and shape of the leg, and is assisted in their decision-making process by the provision of 4 tables.

Patients with a prior history of deep vein thrombosis (DVT) should use a compression system that delivers 30 to 40 mmHg.2 In contrast, patients with no history of DVT may use a compression system delivering 20 to 30 mmHg. Standardized methods based on the manufacturer's recommendations should be used when measuring for compression stockings or devices. Patient education regarding compression stockings/devices should be provided in addition to information about leg health. Periodic reassessment of the lower extremities should occur on a regular basis and at least twice annually.

For patient classified as clinical CEAP 3-4, treatment is based on results of ABI (ABPI) measurement. If the ABI/ABPI is <0.5 (indicating clinically relevant ischemia from arterial disease) or >1.3 (indicating possible arterial disease with noncompressible vessels) compression should not be applied.47 Instead, the clinician should educate patient and caregiver on leg health and consider referral for evaluation and management of significant arterial disease and pharmacotherapy in selected cases. Periodic patient reassessment of the lower extremities should occur on a regular basis (at least every 6 months).

Patients with an ABI/ABPI of 0.5 to 0.8, indicating mixed venous and arterial disease, may be managed by modified light compression/support up to 30 mmHg, depending on the individual's tolerance.2,8 If the patient's ABI/ABPI is 0.8 to 1.3, a higher level of compression is indicated. Standardized methods based on the manufacturer's recommendations should be used when measuring for compression stockings or devices. Patient education regarding compression stockings/devices should be provided in addition to information about leg health and pharmacotherapy when indicated. A previous history of DVT also influences the desired level of compression.2 When dermatitis or eczema is observed, treatment with topical steroids is indicated, long with referral to a dermatologist if treatment is ineffective.29 The algorithm also guides the clinician to consider referral to a specialist for further testing and intervention if indicated. Periodic patient reassessment is recommended at least every 6 months to identify any new problems with the legs and to evaluate status of ongoing compression therapy.

Clinical CEAP 5 is characterized by a patient who has experienced a VLU that has now healed. Compression continues to be a mainstay of treatment for all patients with clinical CEAP 5 CVI. As with clinical CEAP 3-4, ABI/ABPI is used to determine the level of compression. If the person's ABI/ABPI is less than 0.5 or more than 1.3, further evaluation is required before compression is considered.47 The clinician should educate the patient and the caregiver on leg health including pharmaceuticals if applicable. An ABI/ABPI of 0.5 to 0.8 indicates mixed venous and arterial disease; these persons may require modified light compression/support up to 30 mmHg, based on patient tolerance.2,8 For patients whose ABI (ABPI) is 0.8 to 1.3, higher compression is indicated. When selecting the type and level of compression, the same considerations must be given to individual patient characteristics as those described earlier. Standardized methods based on the manufacturer's recommendations should be used when measuring for compression stockings or devices. If dermatitis/eczema is present, treatment with topical steroids is indicated with referral to a dermatologist if treatment is ineffective. Patient education regarding compression stockings/devices should be provided in addition to information about leg health and pharmacotherapy when indicated. The clinician is guided to consider referral to the specialist for further testing and intervention if indicated. Periodic patient reassessment of the lower extremities should occur at least every 6 months.

Individuals with a current VLU are classified as clinical CEAP 6. Topical treatment of the ulcer is the primary consideration beginning with wound bed preparation. The 3 components of wound bed preparation are debridement of nonviable tissue, recognition and treatment of wound infection, and moisture balance management within the wound. Moisture balance management is critical with exudative wounds such as VLUs to promote healing and prevent periwound moisture-associated skin damage. There are a variety of dressing categories that are absorbent (eg, hydrocolloids, alginates, gelling fibers, foams, superabsorbents) which will wick the VLU exudate from the wound and periwound area.48 However, managing periwound moisture-associated skin damage is a balancing act; avoiding both excessive dryness seen with venous stasis dermatitis, and excessive moisture in the wound and periwound skin can be challenging. In addition, a nonsensitizing emollient should be used under compression to prevent dermatitis.29 Topical steroids may be used to treat dermatitis; referral to a dermatologist if treatment proves ineffective within a period of 2 to 4 weeks.

The algorithm directs clinicians to obtain an ABI/ABPI because it assists the clinician in determining the level of compression. An ABI/ABPI <0.5 indicates severe arterial disease and a contraindication for use of compression.47 In this case, the clinician is guided to consider referral for evaluation and management of significant arterial disease. Patients with an ABI/ABPI of 0.5 to 0.8 are diagnosed as having mixed venous and arterial disease. This individual may require modified light compression/support up to 30 mmHg, based on tolerance. For patients whose ABI/ABPI is 0.8 to 1.3, higher compression is indicated.2,8 When selecting the type and level of compression, the same considerations must be given to individual patient characteristics as those described earlier. Standardized methods based on the manufacturer's recommendations should be used when measuring for compression stockings or devices. Dermatitis or eczema should be treated as described previously. Patient education regarding compression stockings/devices should be provided in addition to information about leg health and pharmaceuticals. If the wound fails to improve or deteriorates, barriers to healing should be evaluated. The clinician is guided to consider referral to the specialist for advanced adjuvant therapies. Periodic patient reassessment of the success of compression therapy should occur on a regular basis, at least every 6 months and more frequent reassessment may be indicated based on wound characteristics and response to treatment. If treatment is effective, current therapy should be continued until the wound heals. Once the wound heals, the clinical CEAP level changes to clinical CEAP 5 and the clinician is guided to clinical CEAP 5 section of the algorithm.

Supplemental Materials

Multiple supplemental materials were embedded into the algorithm in order to guide clinicians with variable expertise in CVI and VLU when using compression for prevention and management of VLU in persons with CVI. Because the ABI/ABPI is critical to the diagnostic process, a quick-reference guide, including an interpretive table,47 is provided. To further assist with diagnosis, appendices from the WOCN Society's Guideline for Management of Wounds with Lower Extremity Venous Disease have been included.37 These assist the user in discerning among edema, lymphedema, and lipedema, and distinguishing venous eczema from cellulitis. A reference regarding wounds of other etiologies has also been provided.49

When clinical findings indicate CVI, a reference table with photos is available to assist the user in determining the clinical CEAP level. Photographs are included to aid in rapid and accurate assessment.

Additional tools for selecting the type and level of compression are provided. A table entitled Compression Therapies lists the type of compression with brand-name examples and performance characteristics. A Formulary table provides detailed information about wraps, garments, and intermittent pneumatic compression pumps. Compression Stocking Classifications for the United States and the United Kingdom are included in a separate table. A key resource for those less familiar with compression therapy is the Special Considerations Table, which includes information pertinent to all patients as well as unusual patient situations. Clinical references for the use of horse chestnut seed oil and pentoxifylline have also been included in a table.

DISCUSSION

An evidence- and consensus-based algorithm for Compression in CVI with or without VLU was developed and its content validity established. Algorithm construction followed a structured pathway and combined current best evidence to support pathways and decision points within the algorithm with consensus-based decision points when supportive evidence was lacking. Face validity was assessed at multiple points as the algorithm was constructed. In addition, the initial draft of the algorithm was subjected to scrutiny by a consensus panel of 20 clinicians and researchers with expertise in CVI and VLU, resulting in substantive and meaningful changes.

Following construction of a second draft, the algorithm was subjected to review by an independent panel of 21 expert clinicians. The overall content validity index for the algorithm was robust at 0.86 and the indices for the 9 pathways of the algorithm were equally strong varying from 0.86 to 1.0 (Table 7). The algorithm was designed for adult patients in acute care facilities, long-term acute care facilities, outpatient clinics, long-term care/skilled nursing homes, and home care settings. It was constructed to assist clinicians in these health care settings to determine need for and correctly apply compression for persons with CVI with or without VLU.

However, the algorithm is not meant to provide comprehensive management of CVI with or without VLU. We acknowledge that adjunctive therapies, including pharmacotherapy, remain controversial. Nevertheless, their presence in the algorithm reflects their presence in the daily practice of many clinicians managing patients with CVI with or without VLU rather than an endorsement of these medications, given the paucity of evidence. The algorithm provides evidence- or consensus-based guidance toward selection of product categories when choosing compression; it intentionally avoids recommendation of any specific products. Such choices are profoundly influenced by local factors such as clinician comfort with certain products, facility considerations such as contractual arrangements, and individual patient factors such as tolerance, affordability, and access to specific products.

CONCLUSION

A consensus- and evidence-based algorithm was constructed to aid clinicians select and apply compression for primary prevention, treatment, and prevention of recurrent VLU in patients with CVI. Nurses, physicians, physical therapist, and occupational therapists practicing in all health care settings are strongly encouraged to adapt this algorithm into their practice.

REFERENCES